Spironolactone in Covid-19 Induced ARDS

The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04345887

Enrollment

Registered

2020-04-15

Start date

2020-05-05

Completion date

2020-07-05

Last updated

2021-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome, Adult

Brief summary

This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.

Interventions

DRUGSpironolactone 100mg

2x100 mg spironolactone for 5 consecutive days

DRUGPlacebo oral tablet

2 x1 placebo tablet

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Hemodynamically stable * Hypoxemia, i.e. p/f \<150 * Admitted to ICU within 48 hours * Not moribund has a life expectancy greater than 24 hours

Exclusion criteria

* Age criteria * Pregnancy * Unwillingness to participate

Design outcomes

Primary

Measure	Time frame	Description
p/f ratio	5 days	improvement in oxygenation

Secondary

Measure	Time frame	Description
SOFA	5 days	improvement in SOFA Score

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026